DK2077268T5 - Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme - Google Patents

Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme Download PDF

Info

Publication number
DK2077268T5
DK2077268T5 DK09150953.9T DK09150953T DK2077268T5 DK 2077268 T5 DK2077268 T5 DK 2077268T5 DK 09150953 T DK09150953 T DK 09150953T DK 2077268 T5 DK2077268 T5 DK 2077268T5
Authority
DK
Denmark
Prior art keywords
compound
formula
reacting
preparing
amino
Prior art date
Application number
DK09150953.9T
Other languages
English (en)
Other versions
DK2077268T3 (da
Inventor
Richard Hubert Furneaux
Peter Charles Tyler
Vern L Schramm
Original Assignee
Victoria Link Ltd
Albert Einstein College Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria Link Ltd, Albert Einstein College Medicine Inc filed Critical Victoria Link Ltd
Publication of DK2077268T3 publication Critical patent/DK2077268T3/da
Application granted granted Critical
Publication of DK2077268T5 publication Critical patent/DK2077268T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (8)

  1. Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme
    1. Forbindelse med formlen:
    hvori Y er en ikke-substitueret eller substitueret alkyl-eller arylalkyl-gruppe med 1 til 8 carbonatomer.
  2. 2. Forbindelse ifølge krav 1, som er 3-amino-2-ethoxycarbonylpyrrol.
  3. 3. Fremgangsmåde til fremstilling af forbindelsen 3H,5H-pyrrolo[3,2-d]pyrimidin-4-on, omfattende trinnet med omsætning af en forbindelse med formlen (A) ifølge krav 1 med et reagens, der er i stand til at frembringe en formyl-ækvivalent.
  4. 4. Fremgangsmåde ifølge krav 3, hvori reagenset, der er i stand til at frembringe en formyl-ækvivalent, er formamidinacetat.
  5. 5. Fremgangsmåde ifølge krav 3 eller 4, hvori forbindelsen med formlen (A) er forbindelsen 3-amino-2-ethoxycarbonylpyrrol.
  6. 6. Fremgangsmåde til fremstilling af en forbindelse med formlen (A) ifølge krav 1 omfattende følgende trin: (a) omsætning af isoxazol med alkoxid-ioner i tilstedeværelse af en alkohol; (b) standsning af reaktionen med en syre; (c) omsætning af den resulterende reaktionsblanding med en dialkylaminomalonat; (d) isolering af en organisk fase af den resulterende reaktionsblanding og reducering af den til en rest; og (e) omsætning af resten fra den organiske fase med en base i et protisk eller aprotisk opløsningsmiddel, så der dannes en forbindelse med formlen (A).
  7. 7. Fremgangsmåde ifølge krav 6, hvori forbindelsen med formlen (A) er 3-amino-2-ethoxycarbonylpyrrol, og trinnet (e) omfatter omsætning af resten fra den organiske fase med ethoxid-ioner i et overskud af ethanol.
  8. 8. Fremgangsmåde til fremstilling af forbindelsen 3H,5H-pyrrolo[3,2-d]pyrimidin-4-on omfattende følgende trin: (a) fremstilling af en forbindelse med formlen (A) ved en fremgangsmåde ifølge krav 6 eller 7; og (b) omsætning af den således fremstillede forbindelse med formlen (A) med et reagens, der er i stand til at frembringe en formyl-ækvivalent.
DK09150953.9T 1999-04-08 2000-04-07 Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme DK2077268T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ33509099 1999-04-08
NZ33616899 1999-06-08
EP00917509A EP1165564B1 (en) 1999-04-08 2000-04-07 Process for preparing inhibitors of nucleoside metabolism

Publications (2)

Publication Number Publication Date
DK2077268T3 DK2077268T3 (da) 2017-06-06
DK2077268T5 true DK2077268T5 (da) 2017-08-28

Family

ID=26652045

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09150953.9T DK2077268T5 (da) 1999-04-08 2000-04-07 Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme
DK00917509T DK1165564T3 (da) 1999-04-08 2000-04-07 Fremgangsmåde til fremstilling af inhibitorer af nukleosidmetabolisme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00917509T DK1165564T3 (da) 1999-04-08 2000-04-07 Fremgangsmåde til fremstilling af inhibitorer af nukleosidmetabolisme

Country Status (18)

Country Link
US (4) US6693193B1 (da)
EP (2) EP1165564B1 (da)
JP (2) JP4430247B2 (da)
KR (1) KR100755110B1 (da)
CN (2) CN101062928B (da)
AT (1) ATE425165T1 (da)
AU (1) AU776540C (da)
CA (3) CA2634299C (da)
CY (2) CY1109103T1 (da)
DE (1) DE60041757D1 (da)
DK (2) DK2077268T5 (da)
ES (2) ES2324016T3 (da)
HK (2) HK1088310A1 (da)
LT (1) LT2077268T (da)
NZ (1) NZ514660A (da)
PT (2) PT1165564E (da)
SI (2) SI1165564T1 (da)
WO (1) WO2000061783A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
WO2000061783A2 (en) * 1999-04-08 2000-10-19 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US7109331B2 (en) 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
CA2496698C (en) 2002-08-21 2012-01-24 Albert Einstein College Of Medicine Of Yeshiva University 5-h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
US6972331B2 (en) 2003-04-23 2005-12-06 Biocryst Pharmaceuticals, Inc. Carboxy pyrrole, process of preparing and use as precursor
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
NZ533360A (en) * 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
AU2006275725A1 (en) * 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
WO2007097643A1 (en) * 2006-02-22 2007-08-30 Industrial Research Limited Analogues of coformycin and their use for treating protozoan parasite infections
AU2007218334A1 (en) * 2006-02-24 2007-08-30 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
JP2009527550A (ja) * 2006-02-24 2009-07-30 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 癌を処置する方法
CN101094080B (zh) * 2006-06-22 2012-06-20 华为技术有限公司 一种即按即通系统中的计费方法
CN101528749B (zh) 2006-09-07 2013-07-31 工业研究有限公司 核苷磷酸化酶和水解酶的无环胺抑制剂
EP2049543B1 (en) 2006-09-07 2014-11-05 Callaghan Innovation Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
WO2008079028A1 (en) 2006-12-22 2008-07-03 Industrial Research Limited Azetidine analogues of nucleosidase and phosphorylase inhibitors
EP2278999A4 (en) 2008-04-21 2015-04-22 Otonomy Inc EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2348854A4 (en) * 2008-09-22 2012-03-14 Einstein Coll Med METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING
WO2011008110A1 (en) 2009-07-17 2011-01-20 Albert Einstein College Of Yeshiva University 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
WO2012074912A1 (en) 2010-11-29 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
US20130338178A1 (en) 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US11114184B2 (en) 2017-02-21 2021-09-07 Albert Einstein College Of Medicine DNA methyltransferase 1 transition state structure and uses thereof
CN110590786B (zh) * 2019-09-29 2021-12-03 上海大学 9-去氮鸟嘌呤合成工艺的改进方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59307270D1 (de) * 1992-11-06 1997-10-09 Ulrich Rindlisbacher Vorrichtung zum befestigen an einem gestell eines zweiradfahrzeugs
IL107616A0 (en) 1992-11-18 1994-02-27 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs
US6379911B2 (en) * 1996-02-23 2002-04-30 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000061783A2 (en) * 1999-04-08 2000-10-19 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US6448799B1 (en) * 1999-09-30 2002-09-10 Hitachi Electronics Engineering Co., Ltd. Timing adjustment method and apparatus for semiconductor IC tester
US7109331B2 (en) * 2000-08-29 2006-09-19 Industrial Research Limited 5H-pyrrolo[3,2-d]pyrimidine nucleoside metabolism inhibitors
US6458799B1 (en) 2000-08-31 2002-10-01 Biocryst Pharmaceuticals, Inc. Deazaguanine analog, preparation thereof and use thereof
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
CA2496698C (en) 2002-08-21 2012-01-24 Albert Einstein College Of Medicine Of Yeshiva University 5-h-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
US20090012104A1 (en) 2004-07-27 2009-01-08 Babu Yarlagadda S Inhibitors of 5'-Methylthioadenosine Phosphorylase and 5'-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
AU2007218334A1 (en) 2006-02-24 2007-08-30 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
JP2009527550A (ja) 2006-02-24 2009-07-30 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 癌を処置する方法

Also Published As

Publication number Publication date
SI2077268T1 (sl) 2017-07-31
US7022852B2 (en) 2006-04-04
US20060089498A1 (en) 2006-04-27
AU776540C (en) 2006-01-05
CY1109103T1 (el) 2014-07-02
PT2077268T (pt) 2017-06-12
US6693193B1 (en) 2004-02-17
SI1165564T1 (sl) 2009-08-31
EP1165564A4 (en) 2003-01-22
CN101062928A (zh) 2007-10-31
CA2696826A1 (en) 2000-10-19
CN1196704C (zh) 2005-04-13
EP1165564A2 (en) 2002-01-02
EP2077268A1 (en) 2009-07-08
ES2625636T3 (es) 2017-07-20
CA2368095C (en) 2009-10-06
EP2077268B1 (en) 2017-03-01
DK2077268T3 (da) 2017-06-06
CY1119099T1 (el) 2018-02-14
US20070161667A1 (en) 2007-07-12
EP1165564B1 (en) 2009-03-11
JP2009173673A (ja) 2009-08-06
LT2077268T (lt) 2017-08-10
KR20020018658A (ko) 2002-03-08
KR100755110B1 (ko) 2007-09-04
NZ514660A (en) 2004-03-26
DE60041757D1 (de) 2009-04-23
CA2696826C (en) 2013-01-08
AU776540B2 (en) 2004-09-16
US7211677B2 (en) 2007-05-01
CA2634299C (en) 2011-05-31
CN1370171A (zh) 2002-09-18
AU3846900A (en) 2000-11-14
WO2000061783A3 (en) 2001-02-08
CN101062928B (zh) 2010-10-06
ES2324016T3 (es) 2009-07-29
PT1165564E (pt) 2009-04-16
JP4430247B2 (ja) 2010-03-10
US7405297B2 (en) 2008-07-29
US20040181063A1 (en) 2004-09-16
ATE425165T1 (de) 2009-03-15
JP2002542170A (ja) 2002-12-10
CA2368095A1 (en) 2000-10-19
HK1116472A1 (en) 2008-12-24
WO2000061783A2 (en) 2000-10-19
DK1165564T3 (da) 2009-06-08
JP5070237B2 (ja) 2012-11-07
CA2634299A1 (en) 2000-10-19
HK1088310A1 (en) 2006-11-03

Similar Documents

Publication Publication Date Title
DK2077268T5 (da) Fremgangsmåde til fremstilling af hæmmere af nukleosidmetabolisme
EP2433943B1 (en) Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity
WO2013049605A1 (en) Processes for the preparation of an intermediate in the synthesis of eltrombopag
US20090137803A1 (en) 5-protected aminopyrimidine compound, production method thereof and intermediate therefor
RU2447073C2 (ru) Способ получения абакавира
EP3794001B1 (en) Intermediates and processes for the preparation of linagliptin and its salts
US8093384B2 (en) Processes for the preparation of alfuzosin
ES2685837T3 (es) Proceso y productos intermedios para la síntesis de derivados de (3-alquil-5-piperidin-1-il-3,3a-dihidropirazolo[1,5-a]pirimidin-7-il)-amino
JP2002155059A (ja) ４−アミノ−５−シアノイミダゾール誘導体及びその中間体の製造方法
KR20190131983A (ko) 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
KR20070020568A (ko) 누클레오시드 대사 억제제의 제조방법
JPH035462A (ja) １―（２―クロロエチル）―２―メチル―５―ニトロイミダゾールのの製造方法
WO2013080218A1 (en) Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts